Previous studies revealed that the downregulation of MHC-I expression in cancer cells is a crucial factor that inhibits both the antitumor effect of type II IFN signaling and the infiltration of CD8+ T cells [19, 20]. The gene discussed is CD8A; the disease is cancer.